CRY2 THERAPEUTIC USE OF FUSION PROTEIN HAVING MODIFIED CRY2 AND THERAPEUTIC USE BASED THE SAME

摘要

Disclosed are a CRY2 variant fusion protein with improved photosensitivity and therapeutic use using the same. The fusion protein comprises _{at least one of E279 and E281 having a negative charge among the N 277} SEGE ₂₈₁ sequences of SEQ ID NO: 1 alanine (A), isoleucine (I), leucine (L), valine (V), phenylalanine (F), methionine (M), and tryptophan (W), substituted with any one selected from the neutral amino acid group consisting of, or any one of S278 and G280 in _{the N 277SEGE 281} sequence of SEQ ID NO: 1 is bulky consisting of tryptophan (W) and phenylalanine (F) CRY2 variant substituted with any one selected from one amino acid group, receptor tyrosine kinase (RTKs) bound to the terminal of the CRY2 variant, receptor tyrosine kinase (RTKs) variants in which the ligand binding site is removed or the ligand is not bound; STIM1 or a fusion protein of STIM1 in which the ligand binding site is removed or the ligand is not bound.